1 completed, 1 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow molibresib: new trials by email Literature Review of molibresib trials Research Report on molibresib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma Cisplatin, Etoposide, Etoposide Phosphate - Metastatic NUT Carcinoma, Unresectable NUT Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2020-09-18 | 2020-09-28 | |
| A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies GSK525762 - Neoplasms | Phase 2 | Completed | GlaxoSmithKline | 111 | 2014-05-14 | 2024-10-01 |
Leukemia (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Neoplasms (1)
GlaxoSmithKline (1) · National Cancer Institute (NCI) (1)
Australia (1) · South Korea (1) · Spain (1) · United Kingdom (1) · United States (1)
UM1CA186709 (1)